The startup has developed a biomolecule copying technology that enables the efficient production and replication of microarrays, facilitating research in tumor and autoimmune therapies. This technology simplifies the complex interactions of the immune system, enhancing capabilities in diagnostics, vaccine development, and lead screening.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The conventional methods of discovering and developing biotherapeutic drugs for cancer are often slow, costly, and carry a risk of failure during the transition from early-stage discovery to industrial-scale production. Existing biotherapeutics may also damage healthy cells, leading to life-threatening side effects.
Solution
BioCopy provides an AI-powered, end-to-end automated platform that accelerates the discovery and development of next-generation biotherapeutics for cancer. The platform leverages precision screening and an automated lab to analyze a multitude of cancer cell markers and potential biotherapeutics, providing early insights into safety and efficacy. By integrating AI and machine learning with proprietary data, BioCopy can predictively design safer and more effective drug candidates, significantly reducing the time and cost associated with traditional drug development processes. The platform's accelerated development process mimics industrial processes, increasing developmental success rates and redefining time-to-market benchmarks.
Target Audience
BioCopy's primary customers are pharmaceutical companies seeking to accelerate the development of safer and more effective next-generation biotherapeutics for cancer, as well as researchers in the fields of immunology and oncology.
Features
- AI-driven platform for predictive design of next-generation biotherapeutics
- End-to-end automation for high-throughput engineering of multi-specific antibody therapeutics
- Precision screening technology (ValidaTe) for large-scale analysis of cancer cell markers and biotherapeutics interactions
- Automated lab capable of analyzing up to 25,000 drug candidates in parallel
- Proprietary data farms for storing and leveraging drug candidate design data
- Focus on internal cancer cell markers for more precise cancer cell binding and reduced risk of damage to healthy cells
- Building-block method for combining diverse functional components into a single drug candidate